.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Current diagnostic methods for brain tumors often require invasive procedures. Consequently, glioma liquid biopsy has emerged as a critical tool for identifying circulating tumor DNA (ctDNA) in cerebrospinal fluid. However, traditional techniques like digital PCR frequently struggle with low ctDNA abundance and rapid clearance. To address this, researchers have developed an ultrasensitive dual-channel synergistic biosensor that achieves detection limits at the zeptomolar level.
Specifically, the platform utilizes a synergistic design to enhance target-contacted sensing. This biosensor integrates a DNA tetrahedron-hybridization chain reaction-gold nanoparticle cascade. Furthermore, this multi-layered amplification system allows for a dynamic range spanning 12 orders of magnitude. Notably, the optical platform overcomes structural field confinement to deliver unprecedented sensitivity. Therefore, clinicians can now detect mutations using only a microliter of a sample.
Validation studies confirm that this strategy accurately identifies the IDH1.R132H mutation in glioma patients. Moreover, it provides vital clinical data, including tumor staging and size. In addition, the platform is label-free, rapid, and cost-effective, making it highly suitable for longitudinal disease monitoring. Ultimately, this technology offers a powerful solution for early cancer screening and molecular diagnostics in various clinical settings.
Unlike standard droplet digital PCR, this biosensor uses a dual-channel synergistic strategy and cascade amplification. As a result, it achieves a detection limit of 74 zM, which is significantly lower than existing analytical platforms.
Yes, it successfully identifies the IDH1.R132H mutation, a primary biomarker for glioma. This allows for precise staging and monitoring of the disease through a simple 1 \u00b5L sample.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always seek the advice of your physician or another qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Sun Y et al. A Dual-Channel Synergistic Ultrasensitive Biosensor for Tumor Liquid Biopsy. Adv Sci (Weinh). 2026 Apr 27. doi: 10.1002/advs.75443. PMID: 42043839.
Vaishali S et al. Clinical utility of plasma cell-free DNA (cfDNA) in diffuse gliomas for the detection of IDH1 R132H mutation. Pathology - Research and Practice. 2024. doi: 10.1016/j.prp.2024.155571.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A new ultrasensitive biosensor detects glioma ctDNA at zeptomolar levels, offering a rapid, cost-effective tool for IDH1 mutation screening and monitoring....
4 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
